How low is the α/β ratio for prostate cancer?

International Journal of Radiation Oncology Biology Physics

Volumn 55, Issue 1, 2003, Pages 194-203

  Wang, Jian Z ^a   Guerrero, M ^a   Li, X Allen ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Linear quadratic model; Prostate cancer; Radiotherapy; Tumor repopulation

Indexed keywords

CELLS; RADIOTHERAPY; REPAIR; TUMORS;

CLONOGENIC;

DISEASES;

IODINE; PALLADIUM;

ARTICLE; BRACHYTHERAPY; CANCER RADIOTHERAPY; CELL CLONING; CELL COUNT; CONTROLLED STUDY; HIGH RISK POPULATION; HUMAN; IMPLANT; MALE; MATHEMATICAL ANALYSIS; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROBABILITY; PROSTATE CARCINOMA; STATISTICAL ANALYSIS; TIME;

DOSE FRACTIONATION; DOSE-RESPONSE RELATIONSHIP, RADIATION; HUMANS; MALE; MODELS, THEORETICAL; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE;

EID: 0037215315     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(02)03828-2     Document Type: Article

References (38)

1. Brenner D.J., Hall E.J. Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys. 43:1999;1095-1101.
2. Stock R.G., Stone N.N., Tabert A., et al. A dose-response study for I-125 prostate implants. Int J Radiat Oncol Biol Phys. 41:1998;101-108.
3. Hanks G.E., Schultheiss T.E., Hanlon A.L., et al. Optimization of conformal radiation treatment of prostate cancer Report of a dose escalation study . Int J Radiat Oncol Biol Phys. 37:1997;543-550.
4. King C.R., Mayo C.S. Is the prostate α/β ratio of 1.5 from Brenner and Hall a modeling artifact? [editorial] Int J Radiat Oncol Biol Phys. 47:2000;536-538.
5. Brenner D.J., Hall E.J. In response to Drs. King and Mayo Low α/β values for prostate appear to be independent of modeling details . [editorial] Int J Radiat Oncol Biol Phys. 47:2000;538-539.
6. Duchesne G.M., Peters L.J. What is the α/β ratio for prostate cancer? Rationale for hypofractionated high-dose rate brachytherapy. [editorial] Int J Radiat Oncol Biol Phys. 44:1999;747-748.
7. Brenner D.J. Toward optimal external-beam fractionation for prostate cancer. [editorial] Int J Radiat Oncol Biol Phys. 48:2000;315.
8. Fowler J., Chappell R., Ritter M. Is α/β for prostate cancer really low? Int J Radiat Oncol Biol Phys. 50:2001;1021-1031.
9. D'Souza W.D., Thames H.D. Is the α/β ratio for prostate cancer low? [editorial] Int J Radiat Oncol Biol Phys. 51:2001;1-3.
10. King C.R., Fowler J.F. A simple analytic derivation suggests that prostate cancer α/β ratio is low. Int J Radiat Oncol Biol Phys. 51:2001;213-214.
11. Fowler J., Chappell R., Ritter M. The prospects for new treatments for prostate cancer. [editorial] Int J Radiat Oncol Biol Phys. 52:2002;3-5.
12. Brenner D.J., Martinez A.A., Edmundson G.K., et al. Direct evidence that prostate tumors show high sensitivity to fractionation (low α/β ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys. 52:2002;6-13.
13. Haustermans K., Fowler J.F. A comment on proliferation rates in human prostate cancer. [letter to editor] Int J Radiat Oncol Biol Phys. 48:2000;303.
14. Dale R.G. The application of the linear-quadratic dose-effect equation to fractionated and protracted radiotherapy. Br J Radiol. 58:1985;515-528.
15. Dale R.G. Radiobiological assessment of permanent implants using tumor repopulation factors in linear-quadratic model. Br J Radiol. 62:1989;241-244.
16. Thames H.D., Bentzen S.M., Turesson I., et al. Time-dose factors in radiotherapy A review of the human data . Radiother Oncol. 19:1990;219-235.
17. Fowler J.F. The linear-quadratic formula and progress in fractionated radiotherapy. Br J Radiol. 62:1989;679-694.
18. Sachs R.K., Hahnfeld P., Brenner D.J. Review The link between low-LET dose- response relations and the underlying kinetics of damage production/repair/misrepair . Int J Radiat Biol. 72:1997;351-374.
19. King C.R., DiPetrillo T.A., Wazer A.E. Optimal radiotherapy for prostate cancer Predictions for conventional external beam, IMRT, and brachytherapy from radiobiologic models . Int J Radiat Oncol Biol Phys. 46:2000;165-172.
20. 103Pd. Phys Med Biol. 46:2001;2557-2569.
21. 103Pd interstitial source calibration and dosimetry Implication for dose specification and prescription . Med Phys. 27:2000;634-642.
22. Hanks G.E., Hanlon A.L., Pinover W.H., et al. Dose selection for prostate cancer patients based on dose comparison and dose response studies. Int J Radiat Oncol Biol Phys. 46:2000;823-832.
23. Pollack A., Zagars G.K. External beam radiotherapy dose response of prostate cancer. Int J Radiat Oncol Biol Phys. 39:1997;1011-1018.
24. Pollack A., Zagars G.K., Smith L.G., et al. Preliminary results of a randomized dose-escalation study comparing 70 Gy to 78 Gy for the treatment of prostate cancer. (Abstr.) Int J Radiat Oncol Biol Phys. 45:(Suppl. 3):1999;146-147.
25. Zelefsky M.J., Leibel S.A., Gaudin P.B., et al. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys. 41:1998;491-500.
26. Vicini F.A., Kestin L.L., Martinex A.A. The importance of adequate follow-up in defining treatment success after external beam irradiation for prostate cancer. Int J Radiat Oncol Biol Phys. 45:1999;553-561.
27. Stokes S.H. Comparison of biochemical disease-free survival of patients with localized carcinoma of the prostate undergoing radical prostatectomy, transperineal ultrasound-guided radioactive seed implantation, or definitive external beam irradiation. Int J Radiat Oncol Biol Phys. 47:2000;129-136.
28. Levegrun S., Jackson A., Zelefsky M.J., et al. Fitting tumor control probability models to biopsy outcome after three-dimensional conformal radiation therapy of prostate cancer Pitfalls in deducing radiobiologic parameters for tumors from clinical data . Int J Radiat Oncol Biol Phys. 51:2001;1064-1080.
29. Webb S., Nahum A.E. A model for calculating tumor control probability in radiotherapy including the effects of inhomogeneous distributions of dose and clonogenic cell density. Phys Med Biol. 38:1993;653-666.
30. Webb S. Converting 3D dose to biological outcomes Tumor control probabilities (TCP) and normal tissue complication probabilities (NTCP) . Mould R.F., Orton C.G., Spaan J.A.E., et al. The physics of conformal radiotherapy. Advances in technology. 1997;258-287 Institute of Physics Publishing, Bristol, UK.
31. Press W.H., Teukolsky S.A., Vetterling W.T., et al. Confidence limits on estimated model parameters. Numerical recipes in FORTRAN. 2nd ed. 1992;684-694 Cambridge University Press, Cambridge, UK.
32. Algan O., Stobbe C.C., Helt A.M., et al. Radiation inactivation of human prostate cancer cells The role of apoptosis . Radiat Res. 146:1996;267-275.
33. DeWeese T.L., Shipman J.M., Dillehay L.E., et al. Sensitivity of human prostate carcinoma cell lines to low dose rate radiation exposure. J Urol. 159:1998;591-598.
34. Leith J.T., Quaranto L., Padfield G., et al. Radiobiological studies of PC-3 and DU-145 human prostate cancer cells X-ray sensitivity in vitro and hypoxic fractions of xenografted tumors in vivo . Int J Radiat Oncol Biol Phys. 25:1993;283-287.
35. Skarsgard L.D., Skwarchuk M.W., Wouters B.G., et al. Substructure in the radiation survival response at low dose in cells of human tumor cell lines. Radiat Res. 146:1996;388-398.
36. Steel G.G., Deacon J.M., Duchesne G.M., et al. The dose-rate effect in human tumour cells. Radiother Oncol. 9:1987;299-310.
37. Kampinga H.H., Hiemstra Y.S., Konings A.W.T., et al. Correlation between slowly repairable double-strand breaks and thermal radiosensitization in the human HeLa S3 cell line. Int J Radiat Biol. 72:1997;293-301.
38. Brenner D.J., Hall E.J. Conditions for the equivalence of continuous to pulsed low dose rate brachytherapy. Int J Radiat Oncol Biol Phys. 20:1991;181-190.